New York Lawmakers Tackle Prescription Drug Abuse

By: Mahdieh Danesh Yazdi

We have all heard the mortifying tales of recent attacks on pharmacies by addicts looking to steal prescription pain-killers. Most notable perhaps, was the case of David Laffers. Mr. Laffers walked into Haven Drugs in Medford, NY and killed the pharmacist, a store clerk, and two customers, who happened to be in the store, in an attempt to steal prescription pain-killers. He was found to be in possession of thousands of hydrocodone pills during a search of his house. David Laffers was sentenced to life in prison and his wife was sentenced to 25 years for her complicity in the crime. The case shocked and horrified the local community. The incident, however, did bring attention to the subject of prescription drug abuse.  As such, New York State lawmakers have taken several measures to address this issue.

The tragedy in Medford was specifically cited in the justification for Bill S5880. This bill, which was introduced in the New York State Senate, would change hydrocodone, a component of the popular drug Vicodin®, from a schedule III drug to a schedule II drug. Hydrocodone is a schedule II drug in and of itself according to federal and state classifications. However, it is only sold as combination products, and hydrocodone combinations have a schedule III designation. This new legislation would change that designation to schedule II, making it illegal to get refills for the drug without a new prescription.  The bill cites the increase in abuse of hydrocodone as the principle reason behind stricter regulation of this drug. The bill also designates tramadol, another opiate which previously was not classified as a controlled substance, as a schedule III substance.  The bill was referred to the Rules Committee on September 09, 2011 and is currently awaiting approval by the committee.

The Medford tragedy was also cited in the justification for Bill S6066. This bill would hold all practitioners, including pharmacists, who dispense controlled medications responsible for the drugs they dispense to those who abuse them if done “other than in good faith in the course of their practice.” Previous laws held doctors responsible for pills given intentionally to drug abusers but pharmacists were not held accountable. This new law would allow pharmacists who did not exercise due diligence in dispensing narcotics to be charged with a Class B Felony and punished accordingly. This bill has been pre-filed and will be introduced in the New York State Senate on January 4, 2012.

Both laws were introduced by Senator Kemp Hannon (R-Nassau) who is the head of the public health committee of the New York State Senate. It is hoped that such measures would reduce the abuse of prescription drugs and help prevent horrific tragedies such as the one that occurred in Medford.

For more information please visit:

http://open.nysenate.gov/legislation/bill/S5880-2011

http://m.nysenate.gov/legislation/bill/S6066-2011

eMAR

Recent Posts

Oxidative Stress and Its Impact on Vitiligo

By: Zurriya Faran, PharmD Candidate c/o 2031 The visible loss of skin pigmentation often indicates…

2 months ago

Thiamine Metabolic Dysfunction Syndrome: Overview, importance, MOA, and treatment

By: Archana Murugan, PharmD candidate c/o 2029 Overview             Thiamine metabolic dysfunction syndrome (TMDS) refers…

2 months ago

Updated Guidelines for the Treatment of Multidrug and Rifampin-Resistant TB and Promising New Anti-TB Drugs in Phase 2/3 Trials

By: Kevin Lee, PharmD Candidate c/o 2028, Angela Yin, PharmD Candidate c/o 2028             The…

2 months ago

Sixth Year Perspective: Interview with Ariella Zadrima, PharmD Candidate, c/o 2026

By: Aymon Choudhury, PharmD Candidate c/o 2027 APPE questions: How did your APPE rotations shape…

2 months ago

Foundayo: The New Drug in the GLP-1 market

By: Sariah Grant, PharmD Candidate c/o 2027             The rise of glucagon-like peptide -1 receptor…

2 months ago

Should All Drugs be OTC? Risks and Consequences of the FDA Commissioner Statement

By: Amanda Kastel, PharmD Candidate c/o 2027 In February 2026, FDA Commissioner Marty Makary stated…

2 months ago